Your email has been successfully added to our mailing list.

×
0 0 0 0 0 0 0 0
Stock impact report

Icosavax: Tender Offer With Contingent Value Right [Seeking Alpha]

Icosavax, Inc. (ICVX) 
Company Research Source: Seeking Alpha
The CVR includes milestone payouts based on FDA approval and net sales of ICVX products in certain regions. The acquisition is primarily focused on Icosavax's lead candidate, IVX-A12, a potential RSV and hMPV vaccine. Looking for more investing ideas like this one? Get them exclusively at Special Situation Report. Learn More » AstraZeneca (NASDAQ: AZN ) has an outstanding tender offer, presumably closing February 16, to acquire all of Icosavax 's ( NASDAQ: ICVX ) shares for $15 per share in cash, plus a non-tradable contingent value right. The contingent value right or CVR can be worth up to $5 under the right circumstances. The CVR consists of: $4 milestone payout if the FDA approves IVX-A12 (or any vaccine incorporating IVX-A12) in the six years after closing. $1 per share milestone based on $200 million in net sales of all ICVX products in the European Union, United Kingdom, and Canada. This has to be achieved within seven years of the deal closing. IVX-A12 is the Ic Show less Read more
Impact Snapshot
Event Time:
ICVX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
Last price at news event
Since Event
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
Last Price
VWAP
High:
Max Up
High:
Low:
Max Down
Low:
%
Post news range
%
Price change

Price Change Percentage


S&P 500
(SPX)

%

Volume ratio
%

Volume
Ticks

Avg transaction size

Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Opt-in for ICVX alerts
Opt-in for
ICVX alerts

from News Quantified
Opt-in for
ICVX alerts

from News Quantified